Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

China flag China · Delayed Price · Currency is CNY
23.00
-0.20 (-0.86%)
Apr 29, 2026, 3:00 PM CST
7.88%
Market Cap 9.36B
Revenue (ttm) 1.68B
Net Income (ttm) 393.72M
Shares Out 403.41M
EPS (ttm) 0.96
PE Ratio 24.09
Forward PE 17.06
Dividend 0.34 (1.47%)
Ex-Dividend Date Jun 20, 2025
Volume 3,604,800
Average Volume 9,658,423
Open 23.11
Previous Close 23.20
Day's Range 23.00 - 23.30
52-Week Range 20.18 - 35.58
Beta -0.08
RSI 31.99
Earnings Date Apr 17, 2026

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 1,784
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 605116
Full Company Profile

Financial Performance

In 2025, Aurisco Pharmaceutical's revenue was 1.70 billion, an increase of 15.03% compared to the previous year's 1.48 billion. Earnings were 449.21 million, an increase of 26.61%.

Financial Statements

News

There is no news available yet.